... reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the. Chronic Leukaemia Working Party of the. EBMT.
Aug 18, 2023 · This study demonstrates overall poor survival outcomes in patients who underwent allo SCT for treatment of multiple myeloma with long-term ...
Missing: Leukaemia | Show results with:Leukaemia
Mar 21, 2022 · ... transplant relapse prediction score in Multiple. Myeloma patients: a large cohort study from Chronic Malignancies Working Party –. Beksac et ...
Outcomes for Reduced-Intensity Allogeneic Transplantation for Multiple Myeloma: An Analysis of Prognostic Factors From the Chronic Leukaemia Working Party of ...
... reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
Jun 4, 2024 · Among 3,405 patients who underwent salvage allo-HSCT, 5-year OS was 32%. (47) In the attempt to identify prognostic factors, another EMBT ...
In patients presenting at an age under 60 years, 10-year survival is approximately 30%. Multiple myeloma is the ninth most common cause of cancer death among US ...
Apr 4, 2022 · Multiple myeloma (MM) remains incurable for most patients, despite significant improvements in treatment. For patients under the age of 70 years ...
Jul 10, 2020 · For patients up to about 70 years of age, combining the new drugs with autologous (Auto) stem cell transplantation results in median overall ...
The median remission duration post-autoSCT and RICalloSCT was 14 and 43 months, respectively. The 5-year relapse/progression rate, progression-free survival and ...